Research Progress on Neuraminidase Inhibitors Against Influenza Virus
Influenza is an acute upper respiratory tract infectious disease caused by influenza viruses that seriously endangers human health.
September 10, 2025
by Xiaonisha
Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 2)
Influenza is an acute respiratory infectious disease caused by the influenza virus.
July 12, 2024
by Xiaomichong
Based on the Current Status of Drug Research and Development Targeting the Pathogenesis of Influenza (Part 1)
Influenza is an acute respiratory infectious disease caused by the influenza virus.
July 12, 2024
by Xiaomichong
R&D Status of Drugs Based on Influenza Pathogenesis (Part Two)
Influenza virus RNA polymerase is a protein complex composed of PA, PB1 and PB2 subunits. PA has endonuclease activity and can induce proteolysis. PB1 has RNA polymerase activity...
March 16, 2022
by PharmaSources/Xiao Michong
First people dosed with a quadrivalent seasonal flu mRNA vaccine
The Phase I/II trial will assess the safety, reactogenicity and immunogenicity of Moderna’s mRNA-1010 seasonal flu vaccine.
July 9, 2021
by europeanpharmaceuticalreview
Sanofi Invests $425M in Flu Vaccine Manufacturing Facility
Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.
June 18, 2021
by contractpharma
First-in-human universal flu vaccine trial begins
The US National Institutes of Health have begun a first-in-human trial to assess the safety and immunogenicity of a potential universal influenza vaccine candidate, FluMos-v1.
June 3, 2021
by europeanpharmaceuticalreview
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
May 11, 2021
by worldpharmanews
Cell-based seasonal influenza vaccine safe and effective in children
Phase III data shows Seqirus’ cell-based quadrivalent seasonal influenza vaccine was as effective and safe as an equivalent FDA-approved egg-based vaccine in paediatric patients.
May 8, 2021
by europeanpharmaceuticalreview
Cidara Therapeutics signs deal with Janssen for antiviral conjugates to prevent, treat influenza
Cidara Therapeutics announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialise Cidara’s Cloudbreak antiviral conjugates (AVCs) for the prevention and ...
April 6, 2021
by expresspharma
FDA Warns of Potential False Results with Roche Molecular Systems for COVID, Flu Test
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff, point-of-care (POC) facility staff, and health care providers that false positive results can occur with the Roche Molecular Systems, Inc. (Roche) cobas SARS-CoV-2 & ...
March 22, 2021
by americanpharmaceuticalreview
Vaccine development software shows promise in influenza effort, could help defeat coronavirus
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.
March 4, 2021
by worldpharmanews